MCF Advisors’s Guardant Health GH Stock Holding History

MCF Advisors’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.7K	Buy	171 +151	+755%	+$16.4K	﹤0.01%	832
2026 Q1	$1.85K	Buy	+20	New	+$2.01K	﹤0.01%	1206

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

MCF Advisors's GH Position: Q2 2026 in Review

MCF Advisors increased its Guardant Health (GH) stake by 755% in Q2 2026, buying an estimated $16.4K and bringing the position to 171 shares worth $25.7K. The position accounts for ﹤0.01% of the portfolio, ranked #832.

MCF Advisors first reported a position in GH in Q1 2026 and has held it in 2 quarters since. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

MCF Advisors held 171 shares of Guardant Health worth $25.7K as of Q2 2026.
MCF Advisors bought 151 Guardant Health shares in Q2 2026, an estimated $16.4K.
Guardant Health made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #832 holding.
MCF Advisors first reported a position in Guardant Health in Q1 2026 and has held it in 2 quarters since.
597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.